» Articles » PMID: 35209726

Comparison of Peak Expiratory Flow(PEF) and COPD Assessment Test (CAT) to Assess COPD Exacerbation Requiring Hospitalization: A Prospective Observational Study

Overview
Publisher Sage Publications
Date 2022 Feb 25
PMID 35209726
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Acute exacerbation of chronic obstructive pulmonary disease (COPD) resulting in hospitalization is significantly associated with the increased morbidity and mortality, but there is a lack of an effective method to assess it. This study aimed to compare the ability of peak expiratory flow (PEF) and COPD assessment test (CAT) to assess COPD exacerbations requiring hospitalization.

Methods: A cohort of 110 patients with moderate to severe COPD was studied over a period of 12 months, and their daily morning PEFs and CAT scores were recorded throughout the study.

Results: After 12 months of follow-up, 72 patients experienced 156 COPD exacerbations, 74 (47%) that resulted in hospitalization and 82 (53%) that did not result in hospitalization. Change in CAT score from baseline to exacerbation was significantly related to change in PEF and Spearman's rho =0.375 (95% CI, 0.227 to 0.506; p < .001). Change in PEF and CAT score from baseline to hospitalized exacerbation was significantly larger than that from baseline to non-hospitalized exacerbation (p < .05). Multivariable analysis indicated that ΔPEF (OR 1.11, 95% CI 1.06-1.16, p < .001) and ΔCAT (OR 1.64 95% CI 1.18-2.27, p = .003) were independently associated with risk of hospitalized exacerbation. ROC analysis indicated that the optimal cutoff value of ΔPEF for identifying hospitalized exacerbation was 49 L/min (27% from baseline), with a sensitivity and specificity of 82.7% and 76.7% (area under the curve [AUC] = 0.872 (95% CI 0.80-0.944, p < .05). The optimal cutoff value of ΔCAT score for identifying hospitalized exacerbation was 10.5 (63% from baseline), with a sensitivity and specificity of 67.3% and 77.4% [AUC]=0.763 (95% CI 0.67-0.857, p < .05). The AUC of ΔPEF and ΔCAT combined for the identification of hospitalized exacerbation was 0.900 (95% CI 0.841-0.959, p < .05), which was larger than that of ΔCAT or ΔPEF.

Conclusions: ΔPEF and ΔCAT were independently associated with risk of hospitalized exacerbation. Compared with CAT, PEF was superior to identify hospitalized exacerbation. Identification via PEF and CAT combined is more effective than using PEF or CAT alone. These results help to assess the severity of COPD exacerbation and provide valuable information for clinical decision-making.

Citing Articles

Early detection and prediction of acute exacerbation of chronic obstructive pulmonary disease.

Zhang J, Chen F, Wang Y, Chen Y Chin Med J Pulm Crit Care Med. 2024; 1(2):102-107.

PMID: 39170822 PMC: 11332833. DOI: 10.1016/j.pccm.2023.04.004.


Serum metabolomics analysis of patients with chronic obstructive pulmonary disease and 'frequent exacerbator' phenotype.

Ding H, Wang H, Wu D, Zhou F, Zhu J, Tong J Mol Med Rep. 2024; 30(2).

PMID: 38873983 PMC: 11200052. DOI: 10.3892/mmr.2024.13261.


Screening performance of COPD-PS scale, COPD-SQ scale, peak expiratory flow, and their combinations for chronic obstructive pulmonary disease in the primary healthcare in Haicang District, Xiamen City.

Shen X, Yang H, Lan C, Tang F, Lin Q, Chen Y Front Med (Lausanne). 2024; 11:1357077.

PMID: 38654837 PMC: 11035724. DOI: 10.3389/fmed.2024.1357077.


The Diagnostic Evaluation of the SINEH Cardiopulmonary Triage Scale and the Emergency Severity Index in the Emergency Department: A Comparative Study.

VatanKhah M, Malekzadeh J, Sharifi M, Mirhaghi A Emerg Med Int. 2024; 2024:3018777.

PMID: 38558877 PMC: 10980548. DOI: 10.1155/2024/3018777.


Therapeutic effect of phycocyanin on chronic obstructive pulmonary disease in mice.

Li W, Li Y, Wang Q, Liu R, Lu J, Lu W J Adv Res. 2024; 66:285-301.

PMID: 38211884 PMC: 11675062. DOI: 10.1016/j.jare.2024.01.009.


References
1.
Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V . Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012; 380(9859):2095-128. PMC: 10790329. DOI: 10.1016/S0140-6736(12)61728-0. View

2.
Suissa S, DellAniello S, Ernst P . Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality. Thorax. 2012; 67(11):957-63. PMC: 3505864. DOI: 10.1136/thoraxjnl-2011-201518. View

3.
Echevarria C, Steer J, Heslop-Marshall K, Stenton S, Hickey P, Hughes R . Validation of the DECAF score to predict hospital mortality in acute exacerbations of COPD. Thorax. 2016; 71(2):133-40. PMC: 4752621. DOI: 10.1136/thoraxjnl-2015-207775. View

4.
Aaron S, Donaldson G, Whitmore G, Hurst J, Ramsay T, Wedzicha J . Time course and pattern of COPD exacerbation onset. Thorax. 2011; 67(3):238-43. DOI: 10.1136/thoraxjnl-2011-200768. View

5.
Kodgule R, Singh V, Dhar R, Saicharan B, Madas S, Gogtay J . Reference values for peak expiratory flow in Indian adult population using a European Union scale peak flow meter. J Postgrad Med. 2014; 60(2):123-9. DOI: 10.4103/0022-3859.132311. View